CSPC Pharmaceutical Group (HK:1093) has released an update.
CSPC Pharmaceutical Group Limited has announced the conditional marketing approval of Enlonstobart Injection, a new anti-cancer drug, by China’s National Medical Products Administration. The medication, designed to treat recurrent or metastatic cervical cancer patients who have not responded to platinum-based chemotherapy, has shown promising results in improving response rates with a favorable safety profile. The company is also conducting further clinical trials to expand the use of the drug in combination with other treatments.
For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.